NEW YORK, Jan. 13, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of GW Pharmaceuticals PLC ("GW Pharmaceuticals" or "the Company") (Nasdaq: GWPH). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at firstname.lastname@example.org or 212-697-6484.
This investigation concerns whether GW Pharmaceuticals and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act").
On January 10, 2016, The Sunday Times reported that GW Pharmaceuticals, a British biopharmaceutical company known for its multiple sclerosis treatment product Sativex, nabiximols disclosed in its annual fiscal report, that its internal financial controls were not effective as of September 30, 2015, and continued to state that the management had determined that it lacked effective controls over the completeness and valuation of clinical trial accruals. It went on to state that the management does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies. The management also lacks sufficiently precise control to ensure completeness of clinical trial accruals in connection with contractual progress payment liabilities.
Following this news, GW Pharmaceuticals shares fell $3.55, or nearly 6%, to close at $56.31 per share on January 11, 2016.
If you are aware of any facts relating to this investigation, or purchased shares of GW Pharmaceuticals, you can assist this investigation by visiting the firm's website: http://www.bgandg.com/#!gwph/uy6rf. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | firstname.lastname@example.org
SOURCE Bronstein, Gewirtz & Grossman, LLC